Virulizin: Started Phase III study

Lorus Therapeutics Inc. (TSE:LOR; LORFF), Toronto, Ontario Product: Virulizin Business: Cancer Therapeutic category: Immune stimulation Target: Tumor necrosis factor (TNF)-alpha Description: Macroph...